InvestSMART

EMvision Medical Devices Limited (ASX: EMV) - Announcements

- Current share price for EMV : $1.775

ASX company news and announcements for EMvision Medical Devices Limited (EMV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All EMvision Medical Devices Limited (EMV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than EMvision Medical Devices Limited (EMV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for EMvision Medical Devices Limited (EMV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$165 Employee Incentive Plan Issues 10 Sep 2024 9:04AM $2.050 $1.775 fallen by 13.41%
$165 Appendix 4G & Corporate Governance Statement 28 Aug 2024 8:06AM $2.100 $1.775 fallen by 15.48%
$165 Appendix 4E & Annual Report to 30 June 2024 28 Aug 2024 8:06AM $2.100 $1.775 fallen by 15.48%
$165 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2024 8:58AM $1.988 $1.775 fallen by 10.69%
$165 First Responder Device Unveiled 23 Jul 2024 8:42AM $1.995 $1.775 fallen by 11.03%
$165 Stage 3 Recuitment Achieved & FDA Engagement Underway 8 Jul 2024 8:24AM n/a $1.775 n/a
$165 Pilot Production Line Established & $1.25m Grant Received 24 Jun 2024 8:15AM $2.020 $1.775 fallen by 12.13%
$165 Trial data confirms early ischaemia detection capabilities 27 May 2024 8:24AM $1.910 $1.775 fallen by 7.07%
$165 Notification of cessation of securities - EMV 26 Apr 2024 8:26AM $2.200 $1.775 fallen by 19.32%
$165 Quarterly Activities/Appendix 4C Cash Flow Report 24 Apr 2024 8:44AM $2.260 $1.775 fallen by 21.46%
$165 Stage 2 Insights Confirm Diagnostic & Clinical Viability 27 Mar 2024 9:07AM $2.520 $1.775 fallen by 29.56%
$165 ASA Milestone Achieved for $0.6m Grant Payment 13 Mar 2024 9:00AM $2.350 $1.775 fallen by 24.47%
$165 Initial Director's Interest Notice 7 Mar 2024 8:28AM $2.540 $1.775 fallen by 30.12%
$165 Final Director's Interest Notice 7 Mar 2024 8:28AM $2.540 $1.775 fallen by 30.12%
$165 Board Changes 7 Mar 2024 8:25AM $2.540 $1.775 fallen by 30.12%
$165 Becoming a substantial holder 1 Mar 2024 9:41AM $2.250 $1.775 fallen by 21.11%
$165 Cleansing Notice 1 Mar 2024 8:21AM $2.250 $1.775 fallen by 21.11%
$165 Notification of cessation of securities - EMV 1 Mar 2024 8:21AM $2.250 $1.775 fallen by 21.11%
$165 Application for quotation of securities - EMV 1 Mar 2024 8:21AM $2.250 $1.775 fallen by 21.11%
$165 Application for quotation of securities - EMV 1 Mar 2024 8:19AM $2.250 $1.775 fallen by 21.11%
$165 CEO Half Yearly Update 29 Feb 2024 6:35PM $2.250 $1.775 fallen by 21.11%
$165 Half Yearly Report and Accounts 29 Feb 2024 6:29PM $2.250 $1.775 fallen by 21.11%
$165 Proposed issue of securities - EMV 29 Feb 2024 8:10AM $2.070 $1.775 fallen by 14.25%
$165 Strategic A$15.28M Investment from Keysight Technologies 29 Feb 2024 8:07AM $2.070 $1.775 fallen by 14.25%
$165 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 9:16AM $1.850 $1.775 fallen by 4.05%

101 - 125 of 371 results

Page 5 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.